Today: 19 April 2026
Diageo share price slips ahead of Feb 25 results as DGE.L traders brace for Dave Lewis test
23 February 2026
1 min read

Diageo share price slips ahead of Feb 25 results as DGE.L traders brace for Dave Lewis test

London, Feb 23, 2026, 09:08 GMT — Regular session

  • Diageo shares lost ground at the open in London, giving back some of Friday’s sharp gains.
  • Some investors have started moving around ahead of Diageo’s interim results, expected Feb. 25.
  • Tariff chatter swirls as the new CEO makes early moves, turning up the volume.

Diageo (DGE.L) edged down about 0.3% to 1,845 pence as of 0908 GMT on Monday, as investors held back ahead of the spirits company’s interim results expected later this week. The stock traded between 1,832 and 1,857 pence.

Diageo, the owner of Guinness and Johnnie Walker, will post its interim fiscal 2026 results for the half ending Dec. 31 this Wednesday. The webcast begins at 0705 UK time, with management opening the floor to live questions from 0930.

Not an ideal moment. European shares lost ground early, the STOXX 600 down 0.3% as of 0815 GMT, after President Donald Trump ratcheted up the global tariff rate he announced over the weekend, reigniting U.S. trade policy worries.

Diageo surged 3.9% on Friday, closing out the week at 1,851 pence. Nearly 6.95 million shares traded hands. The stock ranged from 1,794.5 up to 1,861 pence over the session, according to price data.

All eyes are now on new CEO Dave Lewis after reports surfaced about a possible overhaul of Diageo’s executive committee, with several members said to be on the way out. The company declined to respond. According to Reuters, Diageo is contending with increased U.S. tariffs, which hit its biggest market.

Macro cues aren’t providing much direction right now. “It weakens the dollar in the sense that it potentially benefits non-U.S. growth,” said Sim Moh Siong, currency strategist at OCBC Bank in Singapore, tying the comment to the court ruling and a tariff move. For multinationals that pull in a big chunk of their revenue from abroad, currency swings can hit quickly. Reuters

Diageo trimmed its outlook yet again in November, cautioning that revenue for fiscal 2026 might stall or slip slightly, pointing to sluggish demand in the U.S. and China. “There’s much more for us to do, and we need to go faster,” finance chief Nik Jhangiani said. Reuters

Wednesday’s numbers might shed light on whether volumes have stabilized, or if the action is just moving elsewhere. Traders are watching for any signals on U.S. demand, the latest on pricing, and signs that costs are getting squeezed by trade conditions.

There’s risk on both sides here. If Diageo signals caution on “organic” growth — sales stripped of currency swings and portfolio changes — or hints that important markets are recovering more slowly than hoped, investors might start to doubt the recent rebound’s staying power.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
RELX shares slip at London open as tariff chaos spooks markets; April update looms
Previous Story

RELX shares slip at London open as tariff chaos spooks markets; April update looms

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares
Next Story

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

Go toTop